EGFR and non-small cell lung carcinoma: Encouraging results for NSCLC patients with actionable genomic alterations included on TROPION-PanTumor01 were reported at the 2021 ESMO Congress, which included 34 patients (median age, 62 years; 56% women) with advanced/metastatic NSCLC73; actionable genomic alterations reported by investigators included ALK (n = 3), EGFR (n = 29) and ROS 1 and RET (both n = 1).